Alligator Bioscience has certainly had a successful 2024 according to its Q3 report. With promising phase II results from its leading drug candidate mitazalimab, strong partnerships, and a clear strategy for the future, the company is poised to make significant strides in cancer treatment. Alligator is continuing to invest in preparing mitazalimab for phase III, to be able to initiate a trial in H1 2025, while maturing its ongoing dialogue with global pharma companies regarding a potential partnership.